Medtronic (MDT) financials
Medtronic revenue and earnings by year
Medtronic's revenue was $36.4 billion in the fiscal year to April 24, 2026, up 8.4% from the year before. Net income was $4.80 billion, 13.2% of revenue. Since the fiscal year to April 28, 2017, revenue has grown 2.3% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Apr 2026 | Apr 2025 | Apr 2024 | Apr 2023 | Apr 2022 | Apr 2021 | Apr 2020 | Apr 2019 | Apr 2018 | Apr 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 36.4 | 33.5 | 32.4 | 31.2 | 31.7 | 30.1 | 28.9 | 30.6 | 30.0 | 29.7 |
| Revenue growth | 8.4% | 3.6% | 3.6% | -1.4% | 5.2% | 4.2% | -5.4% | 2.0% | 0.8% | — |
| Gross profit | 23.6 | 21.9 | 21.1 | 20.5 | 21.5 | 19.6 | 19.5 | 21.4 | 20.9 | 20.4 |
| Gross margin | 65.0% | 65.3% | 65.3% | 65.7% | 68.0% | 65.2% | 67.4% | 70.0% | 69.7% | 68.7% |
| Operating income | 6.5 | 6.0 | 5.1 | 5.5 | 5.8 | 4.5 | 4.8 | 6.3 | 6.6 | 5.4 |
| Operating margin | 17.8% | 17.8% | 15.9% | 17.6% | 18.2% | 14.9% | 16.6% | 20.5% | 22.2% | 18.1% |
| Net income | 4.8 | 4.7 | 3.7 | 3.8 | 5.0 | 3.6 | 4.8 | 4.6 | 3.1 | 4.0 |
| Net margin | 13.2% | 13.9% | 11.4% | 12.0% | 15.9% | 12.0% | 16.6% | 15.2% | 10.4% | 13.6% |
| Diluted EPS | $3.73 | $3.61 | $2.76 | $2.82 | $3.73 | $2.66 | $3.55 | $3.42 | $2.26 | $2.89 |
| Free cash flow | 5.4 | 5.2 | 5.2 | 4.6 | 6.0 | 4.9 | 6.0 | 5.9 | 3.6 | 5.6 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open MDT in Markets.
How Medtronic makes money
Revenue by segment in the quarter to July 31, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Cardiovascular | $3.93B | 40.3% |
| Neuroscience Group | $2.68B | 27.4% |
| Medical Surgical | $2.28B | 23.4% |
| Diabetes Group | $843M | 8.6% |
| Other Operating Segment Misc | $29.0M | 0.3% |
See also: MDT valuation and P/E history · MDT returns
No forecast, no recommendation. This page describes Medtronic from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.